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Abstract: Hepatitis C virus (HCV) is a leading cause of chronic liver disease, including 
chronic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Hepatitis C infection 
associates with lipid and lipoprotein metabolism disorders such as hepatic steatosis, 
hypobetalipoproteinemia, and hypocholesterolemia. Furthermore, virus production is 
dependent on hepatic very-low-density lipoprotein (VLDL) assembly, and circulating 
virions are physically associated with lipoproteins in complexes termed lipoviral particles. 
Evidence has indicated several functional roles for the formation of these complexes, 
including co-opting of lipoprotein receptors for attachment and entry, concealing epitopes 
to facilitate immune escape, and hijacking host factors for HCV maturation and secretion. 
Here, we review the evidence surrounding pathogenesis of the hepatitis C infection 
regarding lipoprotein engagement, cholesterol and triglyceride regulation, and the 
molecular mechanisms underlying these effects. 
Keywords: Hepatitis C virus; lipoproteins; apolipoproteins; apoE; apoB; cholesterol; 
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OPEN ACCESS 
Viruses 2013, 5  
 
 
1293 
1. Introduction 
For the approximately 170 million individuals infected with hepatitis C virus (HCV), there is no 
vaccine available and the standard of care therapeutic options prior to inclusion of direct antiviral 
agents (DAAs) have been effective for only 50% of patients, for the most prevalent phylogenetically 
distinct group by 30% nucleotide sequence, genotype 1 [1]. This presents a major health problem, as 
HCV infection is a leading cause of chronic hepatitis, liver cirrhosis, and liver cancer worldwide. 
Chronic HCV infection is typified by slow progression to cirrhosis and advanced liver disease. Many 
individuals, who acquired the infection as young adults in the 1970s, are now presenting with serious 
liver disease, resulting in an increasing prevalence of hepatocellular carcinoma and cirrhosis over the 
past decade [2]. The recently developed DAAs are becoming a new arm for the standard treatment for 
HCV and promise to increase therapeutic efficacy significantly [1,3–5], but these options are still 
limited by the emergence of resistance mutations. Treatments to date are specifically aimed at 
genotype 1 HCV infection, leaving a large swath of patients without effective treatment. Furthermore, 
those patients who did not respond favorably to the current standard treatment have a decreased 
response rate to DAAs [6,7]. Therefore, while a new era of HCV treatment is on the horizon, the 
pathogenesis and disease resulting from HCV infection remain critical issues that need to be addressed. 
Even before the isolation of HCV as the viral agent causing non-A non-B hepatitis, it was known 
that this pathologic agent had a unique interaction with lipids and lipoproteins. Most notably, the 
accumulation of neutral lipids in cytosolic lipid droplets in hepatocytes was defined as a pathologic 
hallmark of hepatitis C virus infection [8]. Early biophysical characterizations of virus particles in 
patient serum also revealed the virus to be highly heterogenous in buoyant density due to association 
with host lipoproteins [9,10]. The lipoprotein association of the virus particle was examined further 
both from human serum and from particles developed from hepatoma cells in cell culture (HCVcc). 
These characterizations have revealed virus particles that have both aspects of typical virions and 
aspects more similar to host-lipoproteins. These infectious hybrid particle complexes have been termed 
lipoviral particles (LVP) to highlight their complex nature (Figure 1). Since the HCV virion utilizes 
lipoproteins in such a unique way, lipoprotein metabolism research has illuminated understanding of 
the virus-host interactions of HCV. We outline here some of the most intriguing results of the role of 
cholesterol and other lipids in HCV pathogenesis, and describe their role in the steps of the HCV life 
cycle including entry, replication, and assembly. 
2. Lipids, Apolipoproteins, and HCV Pathogenesis 
Clinical evidence indicates that HCV infection is not only intimately linked to the metabolism of 
lipids within the hepatocytes that HCV infects, but dysregulates circulating lipoprotein metabolism as 
well. The liver is the central organ of lipid homeostasis for the entire body, through production and 
uptake of lipoproteins. Triglycerides (TG) are packaged in lipoproteins surrounded by a phospholipid, 
cholesterol, and amphipathic protein monolayer to deliver lipids produced or absorbed from the liver 
and intestine respectively to other organs (Figure 1). While HCV hijacks elements of the very-low 
density lipoprotein (VLDL) secretion pathway for the production of infectious particles, the LVP that 
circulate in an infected individual indicate that HCV virions are not only associated with hepatically 
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derived triglyceride-rich lipoproteins (TRL) containing apoB-100, but are also associated with 
intestinally derived lipoproteins containing apoB-48 [11,12], an isoform of apoB exclusively generated 
from the small intestine. The presence of this subpopulation of LVP indicates an active exchange of 
virions between lipoproteins [12]. Aside from infectious LVP, HCV envelope proteins have been 
detected on the surface of lipoproteins devoid of infectious nucleocapsids, in so called empty LVP 
(eLVP), possibly contributing to the physiopathology of the disease [13]. The functional advantage of 
the association of virions with host lipoproteins has not been completely elucidated, though evidence 
suggests utilization of lipoprotein components may both mediate attachment to lipoprotein receptors, 
and obscure circulating viral particles from immunoglobulin recognition, thereby allowing the virus to 
escape immune surveillance [14,15]. It must be determined whether these mechanisms are clear 
priorities, given the implications in vaccine design and the possibility that abrogating these mechanisms 
may have important clinical significance in preventing infection post-liver transplantation [16,17]. 
Figure 1. Functional comparison between cytosolic lipid droplets, very-low density 
lipoprotein (VLDL), and lipoviral particles (LVP). (A) Hepatic cytosolic lipid droplets 
(LD) and (B) VLDL share common properties and functions albeit in different 
compartments. The lipid components of both LDs and VLDL particles consists of a 
hydrophobic triglyceride and cholesteryl-ester core surrounded by a free cholesterol and 
phospholipid monolayer where amphipathic proteins may be embedded or peripherally 
associated, including adipose differentiation-related protein (ADRP/PLIN2) and Tail 
interacting Protein of 47 kDa (TIP47/PLIN3) for LDs [18,19], and apolipoproteins (apos) 
including apoB, apoE, apoCI-III for VLDL [20]. The functions of these proteins are 
analogous: to stabilize assembly, to provide docking sites for the appropriate receptors and 
regulatory proteins, and to regulate access to underlying lipids [21]. (C) Hepatitis C virus 
(HCV) particles in patient sera circulate in complexes with host lipoproteins as lipoviral 
particles, which are enriched in triglyceride, cholesterol, and several apolipoproteins [22,23].  
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Aside from the physical association of HCV components with lipoproteins, intracellular lipids play 
key roles throughout the HCV life cycle. HCV replication requires numerous factors involved in lipid 
metabolism and HCV assembly and production depends on elements of VLDL assembly. Chronic 
HCV infection is associated with deregulated lipid homeostasis favoring triglyceride accumulation in 
the liver [24,25]. HCV infection may contribute to this accumulation through transcriptional activation 
of lipogenic genes favoring lipid synthesis in patients [26,27]. HCV infected chimpanzees likewise 
revealed transcriptional induction of these genes via activation of sterol response element binding proteins 
(SREBPs), important transcription factors involved in cholesterol and fatty acid regulation [28]. The 
crucial role of the viral proteins core, NS2, and NS4B, in activating of SREBP and the retinoid X 
receptor (RXR) alpha pathways was further confirmed both in transgenic mouse models [29,30], and 
in cell culture systems [31–33]. However, clinical studies have indicated that HCV induced 
overexpression of lipogenic genes may exert a strong influence on inflammation and fibrosis 
progression of the infected liver, rather than causing the lipid accumulation observed in hepatic 
steatosis [34]. Sophisticated stable-label studies indicate that patients with HCV infection have increased 
fatty acid synthesis and diminished cholesterol synthesis compared to uninfected individuals [35]. While 
the studies are limited by patient numbers, stable-label studies may further illuminate HCV-associated 
metabolic disturbances in future studies. 
In HCV infected patients, the prevalence of steatosis is twofold higher than in HBV infected 
patients [36,37], demonstrating a clear correlation between HCV infection and non-alcoholic fatty liver 
(NAFL) disease. This correlation is particularly strong in genotype 3 infection relative to other 
genotypes, suggesting genetic variation of HCV contributes to lipid accumulation. Further evidence of 
a direct effect of the virus is the fact that the steatotic grade correlates with the HCV RNA quantity 
present both in the liver [24], and in the serum of infected patients [38,39]. Those patients with HCV 
infection who manifest steatosis, are also more likely to present hypobetalipoproteinemia (diminished 
serum levels of apoB bearing lipoproteins) and diminished serum cholesterol levels [25,36,40,41]. 
These observations indicate that HCV associated steatosis may be a sequela of diminished triglyceride 
export by modulated apolipoprotein B bearing lipoprotein production [25]. There is a correlation of 
HCV genotype 3 infection with both steatosis and hypocholesterolemia [25]. Recent metabolomic 
analysis also indicates that genotype 3 HCV infection inhibits cholesterol synthesis as there is a lack of 
late step intermediate metabolites in patients infected with genotype 3, but not genotype 2 HCV [42]. 
Indeed, the rate-limiting enzyme of VLDL production, microsomal triglyceride transfer protein (MTP), 
is transcriptionally repressed by HCV gene expression both in vitro [43], and in vivo [44], and 
associates with steatosis [44]. Recent studies suggest that the virus-induced dysregulation of apoB-100 
secretion is mediated by increased ferritin heavy chain levels [45]. Indeed, an inverse correlation between 
ferritin and secreted apoB-100 concentrations is found both in JFH-1 HCVcc and HCV-infected patients, 
indicating a possible explanation for the onset of virus-induced liver steatosis [45]. Steatosis is not 
only caused by HCV, but is also linked to pathogenesis and enhanced disease progression. Chronic 
HCV infection is also strongly associated with insulin resistance, which might be a consequence of 
impaired insulin signaling and activation of inflammatory markers such as TNF-alpha and the 
suppressor of cytokine signaling (SOCS) family proteins. This in turn deregulates fatty acid synthesis 
and leads to hepatic steatosis. In parallel, the HCV core protein increases the activity of peroxisome 
proliferator-activating receptor (PPAR)–alpha and gamma in hepatocytes contributing to deregulation 
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of fatty acid beta-oxydation and insulin sensitivity (for a review see [46]). Finally, Fujino et al. 
demonstrated that lipid metabolism genes like the SREBP family genes expression are modified 
through this mechanism [26]. 
The viral effect on patient serum lipid profile has recently been confirmed in a large scale study in 
China including 11,000 patients that reported HCV viremia statistically associating with lower serum 
cholesterol and TG levels [47]. This pathology can also be observed in transgenic mice expressing the 
HCV polyprotein [30]. Diminished triglyceride levels may also play an important role in the severity 
of the infection, since an Egyptian study highlighted that high circulating TG levels during acute infection 
associates with spontaneous clearance of HCV [41]. Moreover, the VLDL-TG to non-VLDL-TG ratio, a 
measure of the proportion of large TRLs, negatively associated with disease progression; patients with 
more advanced fibrosis were lacking in large TRLs [48]. 
Biochemical analysis of HCVcc using a purification scheme involving an epitope tagged envelope 
protein displayed apoE on the virion surface [49]. The extent of this association is dependent on 
growth conditions, since HCVcc grown in serum free media are less capable of immunoprecipitation 
with apoE antibodies than HCVcc grown in media supplemented with 10% fetal bovine serum [50]. 
Three isoforms of apoE are present in the human population, determined by cysteine residue 
substitutions at positions 112 and 158, termed E2, E3 and E4. These apoE isoforms affect lipoprotein 
uptake by hepatocytes due to differential affinity to LDL receptor (LDLr). Given the primary role of 
apoE in the HCV life cycle, several studies investigated the possibility of a correlation between apoE 
isoform and hepatitis C infection. Using the HCVcc system, it remains controversial, but apoE 
genotype seems to have little effect in altering infectivity [51–54]. Comparison of genotype and allele 
distribution with those of healthy controls yielded evidence of diminished progression of liver disease 
and viral clearance associated with the E2 allele, which may protect against establishment of chronicity 
via defective binding of LVP to the cellular receptors involved in HCV entry [55]. Similarly, apoE4, a 
contributing factor to both Alzheimer’s disease and cardiovascular disorders, appears to have a 
protective effect against HCV infection and slows fibrosis progression relative to other hepatotropic 
viral diseases [56,57]. Studies have suggested important roles in HCV infection played by single 
nucleotide polymorphisms of host genes involved in lipid metabolism, such as LDLr [58] and apoB-100, 
however these studies were limited by population size and conclusive results await the confirmation of 
larger-scale studies.  
As previously mentioned, HCV directly affects the composition of host circulating lipoproteins of 
HCV positive patient sera, for example through the generation of eLVP. These altered lipoproteins 
then in turn induce changes in the lipid metabolism of monocyte-derived macrophages [59]. Analysis 
of the apolipoprotein content of VLDL, LDL, and HDL fractions derived from sera of those with or 
without HCV infection showed a specific decrease in the apoA-I content in the LDL fraction [60]. This 
may represent a depletion of large HDL particles, providing clinical evidence that HCV and host 
lipoproteins are reciprocally influenced [60]. Similarly, Kim et al. observed an induction of apoC-IV 
transcription and increased hepatic triglyceride levels in hepatocytes of patients with chronic HCV 
infection [61]. An in vitro study confirmed aberrant transcriptional stimulation of apoC-IV in the 
presence of core, driven by the KU antigen and the PPAR gamma/RXRalpha complex [61]. 
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Rowell et al. investigated these links clinically by measuring several lipid and lipoprotein 
parameters including total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C),  
high-density lipoprotein cholesterol (HDL-C), apoA-I, -B, -CIII, and -E in the sera of patients who 
both did or did not clear chronic HCV infection. Interestingly, multiple logistic regression analysis 
revealed diminished serum apoC-III levels (−25%) to be the factor that most strongly associated with 
both chronic infection and the increasing severity of hepatic fibrosis. The authors of this study propose 
that apoC-III levels may potentially act as a possible marker of HCV disease progression [62]. 
Several studies have indicated a link between the successful outcome of antiviral treatment and 
observed lipid metabolism parameters of the patient. Both hepatic steatosis and insulin resistance 
impair treatment response to interferon α (IFNα) [63–65]. Moreover, hypobetalipoproteinemia and 
diminished serum cholesterol levels are reversed after effective response to antiviral therapies, 
indicating the direct role of the virus on cholesterol and LDL levels [25,66–68]. However, the 
decreased cholesterol and LDL levels associated with HCV does not appear to translate into a 
cardioprotective role, as carotid atherosclerosis is increased in HCV patients, perhaps due to increased 
insulin resistance and metabolic syndrome [69]. Residues Arg70/Leu91 in the HCV core region, along 
with high LDL-C serum levels are associated with early and sustained virological response [70]. 
Furthermore, interferon sensitivity is characterized by low LVP ratios and low apoE levels along with 
higher LDL-C and IL28B rs12979860 CC in HCV genotype 1 infected patients [71], while  
null-response is associated with increased LVP ratio. Lipoprotein profiles more indicative of metabolic 
syndrome, such as a high triglyceride/HDL ratio; likewise, they were indicative of an increased LVP 
ratio for genotype 1 patients [72]. The association of lipids with peg-interferon treatment response 
suggests that lipid modulation may be an effective strategy to modify interferon sensitivity [71,73]. 
3. Treatments Targeting Lipid Metabolism 
The close relationship between host lipids and the HCV life cycle generates opportunities of new 
therapeutic options that target lipid regulation. Indeed, host factor targeting overcomes viral resistance 
due to emerging escape variants and genotype variability. Several lipid modulating agents, which were 
initially tested for their cardioprotective roles, may increase the efficacy of antiviral therapies, such as 
insulin sensitizing drugs and statins. Since insulin resistance and steatosis can modify antiviral 
treatment outcome, and since IR and steatosis enhance progression of the disease, it has been proposed 
to combine standard of care treatment and administration of insulin sensitizer such as metformin [74] 
or thiazolidinedione to manage insulin resistance and in turn induce a SVR [75,76]. Statins are 
inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a limiting step of 
cholesterol synthesis, and are widely used to modulate cholesterol levels in patients at risk of heart 
disease, or with familial hypercholesterolemia. The combination of statins with standard of care 
treatment can decrease hepatic steatosis and improve standard of care treatment efficacy [77–79].  
Despite promising effects observed in in vitro studies [80], the administration of statins alone lead 
to contradictory effects on HCV viral load [81–84]. However, the combination of statins both with 
IFNα alone, or with IFNα and ribavirin showed a strong synergistic effect [79,85–87]. Other strategies 
are under investigation in clinical trials, such as combination with PPAR agonists, antagonists, or 
nicotinic acid. Promising lipid modulating results in humanized mice and chimp models have indicated 
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utility for apoB antisense miRNA (mipomersen) [88] or micro-RNA 122 (miR-122) antagonists [89] 
for their clinical utility as antivirals [90]. However, proof-of-concept studies for HCV therapy remains 
to be determined. Moreover, natural compounds that affect lipid metabolism such as the grapefruit 
flavonoid naringenin [91,92] as well as Epigallocatechin-3-gallate (EGCG), an anti-oxidant molecule 
isolated from the green tea show an antiviral effect. EGCG inhibits HCV entry at the viral attachment 
step [93,94], and EGCG and derivatives also inhibits viral replication via cyclooxygenase 2 and can 
decrease viral induced inflammation [95]. Green tea compounds as well as naringenin may act as 
interesting natural complement diet to lower the progression of HCV induced liver disease, however 
in vivo clinical trial data are yet not available. 
4. Apolipoproteins and the Viral Particle 
Viral particles purified from patient sera were observed for the first time by electromicroscopy in 
1994 [96]. The particles observed were spherical and heterogeneous in size and density, corroborating 
previous findings [97–99], and confirmed later by several other groups [22,23,100]. Biochemical 
analysis using sucrose gradients of infected patients sera further showed that HCV RNA is distributed 
over a wide range of densities from 1.20 g/cm
3
 to 1.03 g/cm
3
 [101]. The fractions containing the 
highest amount of RNA are between 1.12 g/cm
3
 and 1.04 g/cm
3
 [23,102], though this distribution is 
highly dynamic and affected by lipoprotein metabolism [12]. Density heterogeneity is in part explained 
by association of the virus both with immunoglobulins [22,103] and different lipoprotein  
classes [9,10,22,23,97,102,103]. Associations with lipoproteins were further confirmed by 
immunoprecipitation of the HCV RNA containing fractions with anti-apolipoprotein antibodies against 
apoB [9,23] or apoE [22,23]. A major advance in HCV research occurred in 2005 with the discovery 
that the highly replicative HCV JFH1 strain, was capable of producing infectious virions from select 
hepatoma cell lines in culture [104–106]. Early studies of HCVcc revealed that the majority of HCV 
RNA produced is higher in density than the majority of infectious particles. Analysis of HCVcc largely 
confirmed previous observations obtained with human sera regarding density and size heterogeneity as 
well as the LVP nature of the HCVcc [107]. HCVcc permitted manipulation of HCV producing cells, 
and it quickly became apparent that altering VLDL components had dramatic effects on HCV particle 
production. Chemical inhibition of MTP dramatically inhibits HCVcc production, as well as genetic 
silencing of apolipoproteins apoE and apoB [108,109]. The average density of LVP from human sera 
is lower compared to HCVcc (1.05 g/cm
3
 vs. 1.10 g/cm
3
) [104,105,107]. This can be explained at least 
in part by the differences in the neutral lipid content of the LVP produced in cell culture vs. serum 
derived virions, since the cell type that sustains HCV replication, Huh7, secrete a majority of  
LDL-sized rather than VLDL-sized apoB bearing particles [110]. Density may also vary based on the cell 
type producing the virus [107,111–114]. Indeed, LVP produced in human liver engrafted mice [113], as 
well as in primary human hepatocytes [114], more closely resemble particles purified from patients 
infected with HCV. HCVcc passaged through different animal models or cell types revealed a higher 
specific infectivity of the lowest-density populations [104,105,107,113]. However, engineering of cells 
to produce a majority of VLDL does not radically change the virus distribution to low-density, 
indicating a possible genetic contribution for LVP formation [115]. Analysis of the lipid composition 
of the HCVcc particles revealed similar composition to LDL and VLDL, in cholesterol, cholesteryl 
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esters, phospholipids, and sphingolipids [49,102,116]. The presence of apolipoproteins such as apoE, 
apoB, apoCI, apoA1 have also been reported to be HCVcc components through immunoprecipitation 
studies [11,22,60,108,109,117,118]. It is noteworthy that apolipoproteins play an important role in 
HCV entry, assembly, and export steps [49,60,108,109,118–120]. This is the consequence of VLDL 
remnant uptake, VLDL assembly, and export mechanisms being used by the virus. Indeed, it is 
assumed that HCV highjacks VLDL assembly by associating with nascent VLDL in the ER lumen to 
egress the infected cell [109]. Apolipoprotein content analysis of purified HCVcc showed that each 
particle bears approximately 300 molecules of apoE at its surface [49], a remarkable enrichment since 
the estimates of apoE molecules per VLDL are 5–7 [121]. Apart from apoE, apoC1 has been shown to 
associate with HCV particles derived from the sera of chimpanzees, patient derived LVP, and  
HCVcc [118]. Data indicates that apoCI may play an important role in HCV endosomal fusion 
immediately after HCV entry [122]. In contrast to LVPs, purified HCVcc were not immunoprecipitated 
with anti-apoB antibodies, indicating that HCVcc contain little or no apoB relative to patient-derived 
LVPs. This observation may explain the density shift observed between both LVPs and HCV from 
primary hepatocyte cultures compared to HCVcc [114]. In Caco-2 cells, an intestinal cell line which 
possesses intact VLDL assembly machinery, ectopic expression of E1 and E2 viral glycoproteins give 
raise to capsid-free apoB-bearing TRL that are similar to eLVPs observed in patients [117]. These data 
indicate the close association between HCV glycoproteins and host cell lipoproteins even in the 
absence of viral capsids, a finding recently confirmed in observations of E1/apoB interactions [123]. 
Furthermore, recent evidence suggests that basic residues of HCV E2 protein may be important for the 
infectivity of low-density particles [124]. 
5. Lipoprotein and Cholesterol’s Role in Viral Entry 
Lipoprotein mediated HCV entry may be less important in cell-culture adapted HCV particles; cell 
culture adaptation is accompanied by a shift to higher buoyant density of the viruses i.e., those not 
associated with TRL [125]. Indeed, the virus particles that are higher in density in cell-culture are 
marked by a more rapidly-infecting phenotype than the low-density viruses [126]. One of the first 
identified HCV entry factors was LDL receptor (LDLr), by detecting HCV RNA taken up by the hepatoma 
line HepG2 (Figure 2) [127]. The identification of this HCV receptor is controversial since these cells are 
now known to be incapable of sustaining HCV replication, and whether LDLr is involved in HCV entry or 
a later step in HCV infection is disputed, an issue addressed further below [120,128]. To understand how 
HCV utilizes molecules that play a physiological role in hepatic uptake of lipoproteins, we will review 
the key points of TRL metabolic pathways highlighting aspects that may share overlap with HCV entry. 
TRL are assembled and produced either from enterocytes of the intestine as chylomicrons, or from 
hepatocytes as VLDL. These particles dock onto lipoprotein lipase (LpL) dimers tethered to the lining 
of the endothelium by heparan sulfate proteoglycans (HSPGs) [129]. The enzymatic activity of LpL 
hydrolyzes triglycerides in the core of the lipoprotein into free fatty acids that are absorbed and 
delivered to peripheral tissues such as skeletal muscle or adipose tissue. This enzymatic digestion of 
the hydrophobic core of the TRL results in diminishing the size of the lipoprotein and conversion of 
the lipoprotein to a cholesteryl-ester rich remnant. This lipoprotein modification is likewise 
accompanied by altered apolipoprotein composition, and a fraction of LpL binds to the remnants [130]. 
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Similarly to apoE, LpL is capable of binding TRL remnant surfaces and has a cationic ligand binding 
domain that binds highly sulfated and negatively charged HSPGs. Hepatic lipase (HL) likewise plays a 
similar role as LpL, but acts preferentially on smaller VLDL. 
Figure 2. HCV hepatocyte entry. HCV entry into human hepatocytes is a multi-step 
process in which many host factors are involved including heparan sulfate proteoglycans 
(HSPGs), the low density lipoprotein receptor (LDLr), the scavenger receptor class B type 
I (SR-BI), tetraspanin CD81, the tight junction proteins, claudin-1 (CLDN1) and occludin 
(OCLN), receptor tyrosine kinases (RTKs), and the Niemann–Pick C1-like 1 (NPC1L1) 
(reviewed in [131]). The LVP initially binds HSPGs and LDLR via apoE. Subsequent 
interaction with SR-BI, CD81, CLDN1, and OCLN leads to viral internalization in 
cholesterol-rich microdomains via clathrin-mediated endocytosis. Other entry factors such 
as RTKs and NPC1L1 are regulatory cofactors. RTKs promote viral entry by signal 
transduction inducing CD81–CLDN1 association and membrane fusion [132,133] while 
NPC1L1 likely acts on cholesterol regulation. The factors involved in lipid and lipoprotein 
metabolism that relate to HCV entry step are listed in the red box including lipoprotein 
lipase (LpL), hepatic lipase (HL), and apolipoproteins E, B, CI, and AI (apoE, apoB, 
apoCI, apoAI).  
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Recent evidence has revealed that the hepatic regulation of HSPG expression and sulfation level 
plays a critical role in hepatocyte uptake of TRL remnants. The anatomy of the liver is marked by 
accessibility and exposure to the circulatory compartment. The endothelial lining of the liver has 
discontinuous gaps or fenestrae that act as a sieve where TRL remnants can enter the subendothelial 
space of Disse [134]. It is in this space that apoE on the surface of TRL remnants can encounter and 
interact with highly sulfated, negatively charged HSPGs present on the basolateral surface of 
hepatocytes. The HSPG-sequestered TRL remnants can continue to be lipolytically processed by LpL 
and HL even after docking. Evidence indicates that remnant internalization is a process involving 
multiple molecules with somewhat redundant functionality. LDLr plays a central role in remnant 
uptake [135], however 25%–50% of TRL remnants are still cleared in LDLr−/− mice [135]. One 
molecule that contributes to the functional redundancy in TRL remnant uptake is in the same family of 
proteins as LDLr, and is termed LDL receptor related protein 1 (LRP1) [136]. In mouse studies 
employing genetic knockout in hepatocytes of both LDLr and LRP1, there was a marked increase in 
TRL remnants, whereas inactivation of LRP1 alone did not significantly impact TRL remnant 
clearance, indicating that physiologically LRP1 plays a more minor role in lipoprotein uptake [136]. 
LRP1 and HSPGs form complexes on the hepatocyte surface, acting to modulate TRL remnant binding 
to HSPGs [137]. Recent developments in the understanding of TRL remnant removal have focused on 
understanding the regulation and specificity of HSPGs in remnant uptake. Liver specific inactivation in 
mice of enzymes that regulate the degree of sulfation of proteoglycans on hepatocyte surfaces resulted 
in an accumulation of remnants over and above LDLr inactivation alone [138–140]. An elegant study 
by Stanford et al. demonstrated that inactivation of the hepatically expressed HSPG, syndecan 1, 
results in an accumulation of TRL remnants in mice [141]. Another molecule that plays a role in 
lipoprotein metabolism is the scavenger receptor B-I (SR-BI), which acts as a docking receptor for 
primarily cholesteryl-ester rich HDL to facilitate lipid transfer to the hepatocyte [142]. This is a critical 
role in the reverse cholesterol transport, as mammals do not have a cholesterol catabolic pathway aside 
from hepatic conversion of this lipid to bile acid for excretion and secretion directly into the bile duct 
through the ABCG5/G8 transport complex. Hepatic cholesterol levels are also regulated after billiary 
secretion, as cholesterol is reabsorbed through the activity of Niemann Pick C-I Like I (NPC1L1), a 
cholesterol transport protein principally located on the apical surface of hepatocytes, facing the bile 
canaliculi. This molecule also plays an active role in the intestinal absorption of cholesterol, and the 
specific drug ezetimibe has proven to be effective in lowering cholesterol when used in combination 
with a statin [143]. 
The aspects shared between HCV infection and lipoprotein remnant clearance abound, and evidence 
points to the utilization of many of the molecules that are key players in this pathway playing an 
important role in HCV infection, including LpL, apoE, HL, HSPGs, LDLr, SR-BI, and NPC1L1. LpL 
may play a dual role in the HCV life cycle. Since the enzymatic activity of this protein is to hydrolyze 
the triglyceride core of lipoproteins, it is likewise capable of modifying the LVP. The enzymatic 
digestion of HCV from serum by LpL renders HCV RNA susceptible to degradation by RNAses [144]. 
Andréo et al. determined that LpL facilitated attachment of HCV from patient serum to cells, but 
decreased the infectivity of HCVcc [145]. They proposed that there are two functions of LpL on HCV 
in this context; a structural binding function and a catalytic function. Both of these functions can  
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impede HCV infection. Shimizu et al. determined that the catalytic activity of LpL reduces HCV 
infectivity by changing the lipid and apolipoprotein composition of the viral particle [146]. LpL 
mediated inhibition was confirmed by Maillard et al., who found that physiological concentrations of 
LpL inhibits HCV infection primarily through its bridging function, and to a limited degree via its 
catalytic function [147]. LpL affects attachment and early steps of HCV entry, and blocks 
internalization of the virus particles [147]. The inhibitory effect of LpL on HCV infection may extend 
to the structurally similar HL, since silencing of HL in HCV producing cells results in a ~50% increase 
in viral titer [146]. Recent evidence supports that the host apolipoprotein CIII, which may be a LVP 
component, may diminish the inhibitory effect of LpL, consistent with the activity of these 
apolipoproteins in lipoprotein metabolism [148]. 
Both apoE and LpL function by binding both to TRL remnants, and to HSPGs on the hepatocyte 
surface. Aside from lipoprotein interactions, HCV envelope proteins are capable of binding HSPGs in 
the earliest attachment steps of HCV entry, as assayed using HCV pseudoparticles (HCVpp) [149,150]. 
Since apoE is a component of the viral particle, and is a high affinity ligand for HSPG, Jiang et al. 
examined if HSPG binding of HCV was apoE mediated [151]. Utilization of an apoE recognizing 
antibody pre- and post- attachment steps revealed that blocking apoE inhibits attachment, but not 
particle uptake post-attachment. Mutation of the positively charged residues in the heparan sulphate 
and LDLr binding domains of the apoE of HCV producing cells both diminished HCV’s capacity for 
infection, and rendered the apoE unable to be precipitated by the heparan sulfate analog, heparin [151]. 
However, similar aspects of internalization mechanisms include clustering to cholesterol-rich 
microdomains [152], and the requirement of tyrosine kinase activation to internalize the ligand [132,153]. 
The majority of evidence supports the concept that early steps of HCV entry involving viral 
attachment to hepatocytes is mediated by molecules that play a role in TRL remnant removal. 
Conceptually, this would be advantageous to the virus in utilization of an existing host pathway of 
particle transport from hepatocyte to hepatocyte. ApoE, present on the surface of the infectious virions, 
functions to mediate cell attachment through apoE binding partners [120,151]. ApoE is an amphipathic 
protein that is embedded on the surface of lipoproteins through hydrophobic domains and binds 
negatively charged cell-surface receptors through electrostatic interactions with its positively charged 
residues. ApoE binding partners include multiple proteins such as LDLr, although HSPGs may play an 
especially important role in binding apoE for TRL remnant attachment. Albecka et al. have recently 
demonstrated that while silencing expression of the LDLr gene indeed diminishes infection of Huh7 cells 
with HCVcc, HCV internalization occurs at a slower rate than both IDL and LDL internalization [128]. 
Utilizing an antibody to LDLr during HCVcc exposure markedly inhibited infection. Kinetic studies 
revealed strong inhibition during all steps of infection, indicating that LDLr’s uptake and metabolism, 
the investigators observed that treatment with this antibody indeed affected the cholesterol to 
cholesteryl-ester ratio in the cells. Furthermore, Huh7 cells electroporated with HCV RNA 
demonstrated a difference in reporter gene expression 24 h post-electroporation in the presence of 
LDLr antibody, suggesting that the presence of this antibody affects HCV replication [128]. 
Additionally, soluble LDLr that lacks the regions that tether LDLr to the cell surface and facilitate 
internalization of lipoproteins inhibited HCVcc but not HCVpp infection, presumably by competing 
with LDLr binding sites on the virion surface. These findings indicate that LDLr indeed plays an 
important role in HCV infection, but perhaps not a direct role at the early steps of viral attachment and 
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entry. This is consistent with the apoE isoform not playing a major role in HCVcc infection [51–54]. 
More definitive experiments will need to be performed to conclusively rule out LDLr as an attachment 
factor for HCV infection. 
SR-BI was identified as an HCV receptor due to its direct binding to HCV envelope protein E2 [154]. 
Since its identification, SR-BI has been confirmed to play a key role in HCV entry [155–162]. Indeed, 
therapeutic intervention designed to inhibit SR-BI activity, originally purposed for a cardioprotective 
role by increasing HDL levels [163], may prove to be a promising therapy for HCV infection [164]. 
Although the primary physiological role of SR-BI is in reverse cholesterol transport from HDL to 
hepatocytes, this protein also plays a role in TRL remnant metabolism [165,166]. Recent evidence has 
revealed multiple usage functions of SR-BI in HCV entry. Dao Thi et al. elegantly demonstrated 
differing functions for different HCV subpopulations distinguished by lipoprotein association using 
buoyant density [167]. These functions included attachment of HCV to the cells, an access function of 
HCV entry, and an enhancement function that boosts the infection [167]. While the attachment 
function of SR-BI was important for the higher-density particles and independent of HCV E2 protein, 
access and enhancement were important for more intermediate and lower-density HCV subpopulations, 
and dependent on the lipid transfer activity of SR-BI [167]. Zahid et al. expanded on these findings by 
characterizing anti-SR-BI monoclonal antibodies to find that the post-binding activity can be 
distinguished from the E2 binding function of SR-BI [168]. Again, the lipid transfer function of SR-BI 
was found to be important for this post-binding function [168]. Discovery of the critical aspect of the 
lipid transfer activity of SR-BI points directly to the role of lipids in HCV infection at the point of 
HCV entry aside from attachment. 
Consistent with the role of cholesterol regulation and uptake, recent findings identified the 
cholesterol transporter NPC1L1 as an HCV entry factor [169]. The capability of Huh7 cells to be 
infected by HCVcc is diminished by genetic silencing of NPC1L1, binding by antibodies that 
recognize NPC1L1, and by utilizing a small chemical inhibitor of this transporter, ezetimibe. This 
study further implicated cholesterol metabolism in infection by utilizing an HCVcc mutant, identified 
by cell-culture adaptation, in the envelope protein G451R, which increases both the infectivity and the 
buoyant density of the virus [14,125]. Interestingly Sainz et al. found that this corresponded also to an 
increase in cholesterol content of the virion [169]. This difference in cholesterol composition is 
consistent with cholesterol-rich lipoproteins being higher in buoyant density than triglyceride-rich 
lipoproteins. Treatment of the G451 mutant is more potently neutralized with ezetimibe treatment of 
the target cells than wild type virus, correlating cholesterol content of the virion to usage of NPC1L1 
as an entry factor [169]. Since the majority of NPC1L1 is on the apical membrane of hepatocytes, 
while HCV entry, apart from cell-to-cell spread, is considered to occur on the basolateral surface of  
the cell in proximity to the tight junctions, the role of this entry factor may occur indirectly via 
cholesterol regulation.  
The role of cholesterol has indeed been previously established as playing an important role in HCV 
entry. Depletion of cholesterol from target cell plasma membranes using the cholesterol sequestering 
agent methyl-beta-cyclodextrin inhibits HCV infection using both HCVcc and HCVpp [152]. The 
depletion of cholesterol that occurs by using methyl-beta-cyclodextrin disrupts cholesterol-rich 
microdomains present on the surface of hepatocyte plasma membranes. Plasma membrane proteins 
that localize to these lipid microdomains, such as CD81, are dependent for proper plasma membrane 
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expression [152]. Since cholesterol-rich microdomains are critical for CD81 and this protein plays a 
key role at late steps of HCV infection, it is likely that the locale of HCV entry is a cholesterol-rich 
microdomain in the plasma membrane. Cholesterol quantity, in conjunction with sphingomyelin, has 
been demonstrated to dramatically affect the HCV virion fusion with liposomes, reflecting the last step 
of HCV entry [170]. Interestingly, eLVP generated in cell culture are capable of liposome fusion [171]. 
Sphingomyelinase treatment of cells, which converts sphingomyelin to ceramide, prior to infection has 
been demonstrated to be inhibiting [172]. Increasing the ceramide concentration in the plasma 
membrane diminishes CD81 surface expression, which may in turn diminish the capacity for  
HCV infection [172,173]. Interestingly, the density of the virus that is the most capable of HCV  
fusion is approximately 1.06 g/mL, the same density as LDL, the predominant cholesterol-rich  
lipoprotein [170,174]. While the cholesterol and sphingomyelin rich microdomains within target cells 
were found to be important for HCV infection, it was also shown that the enrichment of these lipids in 
the virion composition is also important for its infectivity [116]. Depletion of cholesterol of the virion 
could be resupplemented with lipid analogs dihydrocholesterol and copranastol [175]. It has been 
proposed that the cholesterol content of the virion may facilitate apoE interaction since this lipid 
facilitates precipitation with antibodies against this apolipoprotein [175]. Together these data indicate 
that not only proteins involved in cholesterol regulation are important for the composition and 
infectivity of HCV, but the lipid composition of both virion and target cell also plays a critical role. 
6. Cholesterol and Viral Replication 
Apart from HCV entry, lipids including cholesterol play critical roles in HCV replication  
(Figure 3). HCV replication was able to be studied extensively before other steps of the HCV life cycle 
by using sub-genomic HCV replicons [176]. Studies revealed that HCV replication occurs on  
cholesterol-rich domains within the cell as part of the HCV replication complex [177]. Inhibition 
of the cholesterol synthetic pathway by inhibiting the rate-limiting step 3-hydroxy-methylglutaryl 
CoA reductase completely disrupted HCV replication [80]. Aside from cholesterol synthesis, this 
could also be due to an earlier branch point of this synthetic pathway that functions to add prenyl 
groups to proteins, namely geranylgeranylation. It was demonstrated that the geranylgeranylation 
of host protein FBL2 binds to HCV nonstructural protein 5A (NS5A), playing a critical role in 
HCV replication [178]. The presence of HCV replication complexes in turn functions to elevate 
the levels of enzymes involved in cholesterol and fatty acid synthesis by activation of  
SREBPs [33,179]. Another transcriptional regulator of cholesterol metabolism that is activated by 
the bile acid catabolic products of cholesterol is the farnesoid X receptor (FXR). Bile acids were 
interestingly found to increase HCV replication through FXR activity [180], though this may be 
genotype specific [181]. 
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Figure 3. Interactions between HCV and lipid regulating factors during HCV replication 
and assembly. In conjunction with PI4K-IIIα (Phosphatidylinositol 4-kinase III α), viral 
proteins induce rearrangement of endoplasmic reticulum (ER)-derived membranes forming 
HCV replication complexes in modified ―membranous webs‖ (MW) in association with 
cytosolic lipid droplets (cLD) [182]. Virion assembly occurs on core-enriched LDs, loaded 
with triglyceride by diacylglycerol acyltransferase-1 (DGAT1) [183]. LD protein Tail 
interacting Protein of 47 kDa (TIP47) binds RNA associated NS5A in replication 
complexes and mobilizes it to these LDs [184]. ApoE binds NS5A, effecting early stages 
of HCV assembly [119]. Packaging of the capsid occurs by viral budding into the ER 
lumen at sites of VLDL synthesis. VLDL synthesis is mediated by microsomal triglyceride 
transfer protein (MTP), which lipidates apoB and luminal ApoE-bound LDs (LuLDs) that 
fuse and mature to form VLDL [21]. Host factors involved in lipid metabolism and HCV 
replication, assembly, and production include those listed in the red box: micro-RNA 122 
(miR-122), sphingomyelin synthases 1 and 2 (SMS1 & 2), F-box and leucine-rich repeat 
protein 2 (FBL2), subtilisin/kexin-isozyme-1 or site-1 protease (SK-I/S1P), ceramide 
transfer protein (CERT), oxysterol binding protein (OSBP), apolipoprotein A1 (apoA1).  
 
Recent evidence suggests that not only cholesterol synthesis, but also sphingolipid synthesis 
contributes to HCV replication. HCV nonstructural proteins function to modify the endoplasmic 
reticulum and cytosolic lipid droplets to form double membrane vesicles containing HCV replication 
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complexes where viral RNA is protected from host RNAses and sensors of the innate immunity that 
would respond to double-stranded RNA [182,185]. The replication complexes utilize cytosolic lipid 
droplets (LDs) as a platform where genome replication occurs in conjunction with viral assembly [186]. 
The lipid composition of replication complexes is not completely established, but it is known that 
HCV replication occurs on detergent resistant membranes, indicating that they are likely rich in both 
cholesterol and sphingolipids [177,187]. HCV infection induces the synthesis of sphingomyelin by 
increasing the expression of the genes encoding sphingomyelin synthases 1 and 2 [188]. Indeed, 
inhibition of sphingolipid synthesis dramatically modulates HCV replication [188,189]. Interestingly, 
genotype specificity appears to play a role in the RNA dependent RNA polymerase NS5B being bound and 
activated by sphingomyelin through enhancement of its binding of the template RNA [190]. While it is not 
completely understood how the lipid composition of these specialized compartments are formed, recent 
evidence indicates a key role for phosphotidylinositol 4-kinase, subtype III alpha (PI4KIIIα) [191]. This 
protein was identified through a siRNA screen of kinases that would affect HCV replication, and 
interestingly, HCV NS5A is able to bind and enhance the kinase activity of this protein. 
An important element of both HCV replication and cholesterol metabolism is the liver-specific  
miR-122, which is the predominant miRNA expressed in the liver and plays a key role in hepatic fatty 
acid and cholesterol metabolism [89]. Deletion of miR-122 results in hepatosteatosis and diminished 
circulating cholesterol and lipoprotein levels, a phenotype also reflected in HCV infected patients [192]. 
Also as in HCV infection, this phenotype may in part be mediated through transcriptional modulation 
of microsomal triglyceride transferase, an enzyme required for lipoprotein production [43,44,193]. 
Furthermore, the absence of miR-122 leads to the development of hepatocellular carcinoma in mice [193]. 
This miRNA is also unique in that it directly binds to the HCV genome and acts to boost its  
replication [194]. In fact, this is one of a few factors that confer permissibility of non-hepatic cells for 
robust HCV infection [52].  
The mechanism of miR-122 enhancement of HCV infection is at least in part due to the 
stabilization of the genome by forming a protein complex with host Argonaute 2, protecting the 
genome from exonucleases [195]. The therapeutic possibility of miR-122 as a target has been explored 
in chimpanzees with HCV infection, yielding promising results [90]. It is an intriguing hypothesis that 
the pathology of HCV relating to lipids could be due to the sequestration of miR-122 into these 
complexes, but the physiological levels of HCV RNA during infection are not likely sufficient to exert 
such an effect and there is no in vivo correlation with HCV RNA and miR-122 levels [196]. The 
interplay between this important regulator of cholesterol and lipid metabolism and the pathologic 
effects of HCV infection remain an interesting aspect of HCV research. 
7. Lipoproteins, Lipids and Cholesterol in Virus Production and Secretion  
LDs are the organelles specialized in the storage and release of lipids. LDs are surrounded by 
proteins belonging to the PAT family like the adipose related protein (ADRP), the tail interacting 
protein of 47kDa (TIP47), and proteins involved in lipid biogenesis [197]. The protein and lipid content of 
the LD fluctuates in response to the metabolic needs of the cell induced by cellular lipases [198]. HCV 
infection also influences the proteins associating with LDs. Following HCV core over-expression LDs 
are enriched in TIP47 and depleted of ADRP [199]. Recent evidence indicates that TIP47 interacts 
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with NS5A, which leads to productive HCV secretion [184]. Core-associated LDs form the viral 
assembly platforms were the nascent virions are produced [185]. Indeed, viral assembly is initiated by 
the association of cleaved core protein to cytosolic LD displacing ADRP. There is a balance between 
the amount of core on the LD surface and virus production [200–203]. This active process is mediated 
by the interaction between the diacylglycerol acyltransferase-1 (DGAT-1) and HCV core. DGAT1, an 
enzyme involved in triglyceride synthesis and luminal LD maturation, targets core to LDs. Its absence 
or inhibition leads to the inhibition of viral assembly and production [183]. Modifications affecting LD 
physiology, including composition, size, and apoB localization also display dramatic effects on HCV 
assembly and secretion [204]. Besides their major role in HCV replication [205], cyclophilins also 
impact HCV secretion. Inhibition of cyclophilins by inhibitors or gene silencing modifies cellular 
protein trafficking, LD size, and apoB subcellular localization [206]. Furthermore, the SREBP protease 
subtilisin/kexin-isozyme-1/site 1protease (SKI1/S1P) affects LD formation altering lipid and ADRP 
content as well as size. Consequently, HCV infection is severely impaired by the use of a specific 
inhibitor or gene silencing of SK-I/S1P [207].  
Comparison of the buoyant density of intracellular and extracellular HCVcc particles suggests that 
the virus associates with VLDL-like structures during its egress, suggesting an intimate link between 
the VLDL synthesis, maturation and secretion process and HCV infectious virion production. Indeed, 
actors of the VLDL synthesis mechanism, like apoB, MTP, apoE and apoA1 have been shown to be 
direct players in the virion production mechanism. In brief, blocking the VLDL synthesis by RNA 
interference towards apoB or apoE or by chemical inhibitors of the MTP or the acyl-coA-synthase 3, 
blocks HCV production without affecting viral replication [60,92,108,109,119,208]. It has been 
reported that nonstructural viral proteins of the subgenomic replicon decreases apoB secretion via MTP 
inhibition, which has a consequence on VLDL synthesis [43], a phenomenon which may be redundant 
also with HCV core protein in the core-transgenic mouse model [209]. These observations correlate 
well with MTP and apoB decrease in HCV genotype 3 infected patients [44,210]. Moreover, apoB and 
apoE inhibition leads to a decrease in intracellular HCV infectivity suggesting a role of both 
apolipoproteins in HCV maturation [109]. 
In parallel to its structural role in VLDL formation, apoB has been shown to be required for HCV 
glycoprotein secretion, albeit in a non-hepatic and non-infectious context [117]. However, a direct 
active role of apoB in HCV production has not been clearly proven in the classical Huh-7 cell culture 
model [211]. The exact role of apoB thus remains elusive. Consistent with the critical nature of 
lipoproteins in the HCV life cycle, Steenbergen et al. observed that the humanized mouse model is 
only capable of sustaining HCV infection if the human hepatocytes repopulated the mouse to the 
extent that the lipoprotein profile reflected the lipoprotein distribution observed in humans [212]. 
Among the apolipoproteins involved in HCV assembly and production, apoE plays a major role. 
ApoE depletion displays a more dramatic effect than apoB or apoA1 in HCVcc production. This is 
likely due to an important role of apoE in HCV assembly [53,108,119,211]. ApoE interacts with NS5A 
during HCV infection [51,119]. Since NS5A is a component of the HCV replication complex, and is 
assumed to bring the replication complex to the LD [185], it is likely that the NS5A-apoE interaction 
helps the building of the viral assembly platforms. Moreover, Coller et al. observed that tetracystein-
tagged core co-transports with apoE-GFP [213]. 
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Viruses of the Flaviviridae family use the secretory pathway of the host cell for their egress. In the 
case of HCV, the secretion pathway is tightly associated with host factors of lipoprotein metabolism, 
suggesting that the virus diverts the VLDL synthesis mechanism for its selective advantage. It has been 
shown that apoE plays a crucial role in viral maturation and secretion. Furthermore, the interaction of 
the oxysterol binding protein (OSBP) with NS5A could play a direct role in HCV secretion. Indeed, it 
has been shown that inhibiting phosphorylation of OSBP and the ceramide transfer protein (CERT) by 
protein kinase D (PKD), a protein recruited at the trans-Golgi network, has dramatic effects on HCV 
maturation and secretion likely due to a subsequent decrease in sphingolipid biosynthesis [214,215]. 
However, in the early phases of HCV infection, an increase in sphingolipid synthesis is observed, as a 
physiologic response to viral replication and membrane reorganization [216]. An extensive siRNA 
screen has been recently performed and demonstrated that most of the host cell proteins involved in the 
HCV secretion are part of the classical trafficking pathway, including the Golgi recycling endosomes, 
microtubules, VAMP1 secretory vesicles, and apoE which co-trafficks with core protein [213]. 
HCV infection is unique in its dependency and modification of host lipid and lipoprotein 
metabolism. The interactions with these pathways contribute to the pathogenesis of the disease, and are 
likely to play important roles in vaccine development, and therapeutic considerations. Furthermore, the 
inclusion of lipid modulating therapies along with DAAs may increase their effectiveness. Since an 
increasing number of patients are administered lipid modulating drugs, it is essential to further 
understand virus/host interactions that affect lipid and lipoprotein metabolism to inform and improve 
treatment options. 
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